Skip to content

US · KNSA · MEDICAL - PHARMACEUTICALS

Kiniksa Pharmaceuticals International, plc (KNSA) intrinsic value and stock valuation

$93.90as of 2026-11-21 · Mkt cap 5.95B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kiniksa Pharmaceuticals International, plc DCF and intrinsic value

InvestorsCraft values KNSA with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from KNSA’s statements →

Kiniksa Pharmaceuticals International, plc Graham Number

Graham Number: $11.70d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals London, GL W1J 7NJ kiniksa.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$677.6M
20162025
Net income
$59M
20162025
Free cash flow
$25.4M
20162025
Total equity
$567.6M+12.7% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$677.6M$423.2M$270.3M$220.2M$38.5M
Operating income$77.2M-$-45.62M-$-25.2M$9.77M-$-156.64M
Net income$59M-$-43.19M$14.1M$183.4M-$-157.92M
EPSd$747.2K-$-604.73K$195.8K$2.6M-$-2.3M
Operating cash flow$25.7M$25.7M$13.3M$5.81M-$-126.3M
Capital expenditure-$-280K-$-280K-$-130K-$-100K-$-20.41M
Free cash flow$25.4M$25.4M$13.2M$5.7M-$-146.71M
Total assets$763.6M$580.6M$526.3M$459.7M$232.8M
Total debt$9.5M$9.86M$12.3M$5.92M$6.05M
Net debt-$-156.1M-$-173.73M-$-95.7M-$-116.8M-$-116.42M
Total equity$567.6M$438.4M$438.8M$396.2M$185M
Cash and short-term investments$414.1M$243.6M$206.4M$190.6M$182.2M
Income statement
20252024202320222021
Revenue$677.6M$423.2M$270.3M$220.2M$38.5M
Cost of revenue$307.4M$60.9M$56.5M$22.9M$9.1M
Gross profit$370.2M$362.3M$213.7M$197.3M$29.4M
Research and development expenses$96.9M$111.6M$76.1M$65.5M$99.3M
Selling, general and administrative expenses$196.3M$168M$129.4M$98M$86M
Other expenses$0.00$128.3M$33.4M$24.1M$830K
Operating expenses$292.9M$407.9M$238.9M$187.5M$186.1M
Cost and expenses$600.3M$468.9M$295.5M$210.4M$195.2M
Interest income$11.7M$9.46M$8.54M$1.25M$100K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.55M$1.7M$2.34M$2.4M$2.35M
Ebitda$90.4M-$-34.46M-$-14.31M$13.4M-$-154.18M
Operating income$77.2M-$-45.62M-$-25.2M$9.77M-$-156.64M
Total other income/expenses, net$11.7M$9.46M$8.54M$1.25M$100K
Income before tax$88.9M-$-36.15M-$-16.65M$11M-$-156.54M
Income tax expense$29.9M$7.04M-$-30.74M-$-172.34M$1.39M
Net income$59M-$-43.19M$14.1M$183.4M-$-157.92M
Weighted average shares outstanding$74.2M$71.4M$70.1M$69.4M$68.6M
Weighted average diluted shares outstanding$79M$71.4M$71.9M$70.4M$68.6M
Balance sheet
20252024202320222021
Cash and short-term investments$414.1M$243.6M$206.4M$190.6M$182.2M
Net receivables$15.6M$41.7M$21.3M$20.3M$3.98M
Inventory$54.9M$26.4M$31.1M$21.6M$3.67M
Total current assets$527.2M$331.8M$276.3M$243.1M$196.5M
Property, plant and equipment, net$11.8M$11M$12.7M$7.04M$8.38M
Goodwill and intangible assets$15.3M$16.3M$17.3M$18.3M$19.3M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$236.5M$248.8M$250M$216.6M$36.4M
Total assets$763.6M$580.6M$526.3M$459.7M$232.8M
Accounts payable$2.03M$2.04M$8.25M$7.9M$1.87M
Short-term debt$2.99M$1.99M$2.25M$3.3M$3.38M
Deferred revenue$31.8M$0.00$310K$0.00$0.00
Total current liabilities$139.2M$100.6M$63.7M$47.1M$44.8M
Long-term debt$6.51M$7.86M$10M$2.62M$2.67M
Deferred revenue, non-current$31.8M$31.8M$12M$12M$0.00
Total non-current liabilities$56.8M$41.5M$23.8M$16.5M$2.94M
Capital lease obligations$6.51M$9.86M$12.3M$5.92M$6.05M
Total liabilities$196M$142.1M$87.5M$63.5M$47.8M
Common stock$20K$20K$20K$20K$20K
Retained earnings-$-462.14M-$-521.14M-$-477.95M-$-492.03M-$-675.4M
Accumulated other comprehensive income (loss)-$-30K-$-160K$10K$40K-$-70K
Total equity$567.6M$438.4M$438.8M$396.2M$185M
Total investments$248.5M$60.1M$98.4M$67.9M$59.7M
Total debt$9.5M$9.86M$12.3M$5.92M$6.05M
Net debt-$-156.1M-$-173.73M-$-95.7M-$-116.8M-$-116.42M
Cash flow statement
20252024202320222021
Net income-$-43.19M-$-43.19M$14.1M$183.4M-$-157.92M
Depreciation and amortization$1.7M$1.7M$2.34M$2.4M$2.35M
Stock-based compensation$30.7M$30.7M$27.2M$25.1M$25.2M
Change in working capital$51.6M$24.8M$1.35M-$-22.57M$690K
Accounts receivable$26.1M-$-20.46M-$-950K-$-16.33M-$-3.91M
Inventory$4.76M$4.76M-$-9.52M-$-17.92M-$-3.67M
Accounts payable-$-6.31M-$-6.31M$350K$6.03M$1.37M
Net cash provided by operating activities$25.7M$25.7M$13.3M$5.81M-$-126.3M
Investments in property, plant and equipment-$-280K-$-280K-$-130K-$-100K-$-410K
Acquisitions, net$0.00$30K$0.00$0.00$0.00
Net cash used for investing activities$37.7M$37.7M-$-29.56M-$-8.08M$128.6M
Common stock issued$0.00$0.00$0.00$3.42M$5.88M
Common stock repurchased-$-7.73M-$-4.98M-$-2.21M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.3M$12.3M$1.5M$2.52M$5.88M
Net change in cash$75.6M$75.6M-$-14.76M$240K$8.22M
Cash at end of period$183.6M$183.6M$108M$122.7M$122.5M
Operating cash flow$25.7M$25.7M$13.3M$5.81M-$-126.3M
Capital expenditure-$-280K-$-280K-$-130K-$-100K-$-20.41M
Free cash flow$25.4M$25.4M$13.2M$5.7M-$-146.71M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kiniksa Pharmaceuticals International, plc

        Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

        CEO
        Sanj K. Patel
        Employees
        366
        Beta
        0.09

        Explore

        Frequently asked questions

        What is the intrinsic value of Kiniksa Pharmaceuticals International, plc (KNSA)?

        Kiniksa Pharmaceuticals International, plc (KNSA) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is KNSA undervalued?

        KNSA trades at a price of $93.90 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.